

By Courier/Email/Hand Delivery
WITHOUT PREJUDICE

Date: July 07, 2026

To,
ISLAMIC REPUBLIC OF IRAN,
MINISTRY OF HEALTH, TREATMENT AND MEDICAL EDUCATION
Food and Drug Organization,
Tehran, Iran.

DIRECTORATE OF FOOD & DRUGS ADMINISTRATION,
Dhanwantari, Opposite Shrine of the Holy Cross,
Bambolim – Goa – 403202,
Email – dfda.goa@nic.in

SUB: Request for investigation in the matter of counterfeit/unlicensed drug –
Finasteride (Finpecia) 1mg Tablets in Iran (**PR# 798862**)

Dear Sir/Madam,

We are writing to inform you about the availability of **Finasteride (Finpecia) 1 mg Tablets** bearing Lot No. 004, Exp. Dt. 09/2027 (**'Product'**) in which to our knowledge and investigation is a counterfeit drug / product.

We have received a complaint was addressed to Cipla Limited (**"Cipla"**) by one Mr. Mahdi Bahrami (**'Complainant'**) with a query of the said product along with the photographs of the same. He wanted to know the genuineness of the said Product.

Cipla promptly acknowledged the Complaint vide email dated January 27, 2026 stating that based on preliminary observations, the Product is not manufactured by Cipla and advised him to refrain from consuming the same. Cipla had also requested for certain other details such as the Purchase invoice, the purchase and usage history of the product Finpecia, by the Complainant, etc. The same has not been provided to us till date.

Upon analysis of the complaint Product photographs, received from the Complainant and internally reviewing our records, it was found that currently Cipla is not selling any products through Farnoush, as mentioned on the complaint Product pack. The last batch of the product Finpecia 1mg Tablets was manufactured and marketed in 2018, within the territory of Iran. Since 2018, no further production or supply of the product Finpecia was carried out in Iran. Additionally, the labelling of the complaint Product does not match the labelling specifications of the genuine product manufactured by Cipla. Therefore, we expressly state that as on the present date, the product Finpecia 1mg Tablets is not being supplied within the territory of Iran by Cipla. **In view of the same, the Product received by the Complainant is a counterfeit which is not manufactured by Cipla.**

Cipla Ltd.

Plot Nos. S-103 to S-105, S-107 to S-112, L-138, L-147, L-147/1 to L-147/3, L-147 A, Verna Industrial Estate, Verna, Salcette, Goa 403722, India.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

Phone +91 22 41916000 Fax +91 22 41916120 E-Mail contactus@cipla.com Website www.cipla.com Corporate Identity Number L24239MH1935PLC002380

We believe that some unknown distributors are marketing and selling similar products in the market by illegal means and are using the trade-name and manufacturing details of Cipla Limited from the products available in the open market. Please note that we outrightly and completely disclaim our responsibility and liability arising out of the use of said Product. We do not endorse the said Product in any manner whatsoever.

The activities as enumerated above are capable of deceiving the members of the trade and public at large into believing that the product emanates from us or is manufactured or is distributed under our approval, license and supervision. Such activity can potentially cause irreparable damage, loss and injury to our business, reputation and goodwill.

Your office is well aware that circulation of spurious and unregistered products can lead to grave and adverse consequences on both consumers and genuine manufacturers. Therefore, keeping in mind the safety and well-being of the patients, we hereby request you to urgently take any and all steps deemed appropriate, in order to curtail marketing, sale, distribution and/or commercialization of counterfeit and unregistered products from such spurious manufacturers.

Please be assured of our full cooperation in the investigation for the said matter. All necessary information as may be required by your office shall be provided to the best of our capabilities.

This is for your information and necessary action.

Thanking you and assuring best of our services and attention at all times.

Yours sincerely,

FOR AND BEHALF OF CIPLA LTD.



Authorized Signatory